Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042200 | 0.76 | TDP1 (0.65) | PKMPOLBTDP1L3MBTL1USP2 | |
| SCHEMBL24323901 | 0.74 | GAA (0.66) | PKMNPC1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13373241 | 0.74 | L3MBTL1 (0.62) | PKMPOLBTDP1NPC1L3MBTL1 | |
| SCHEMBL15872007 | 0.73 | ALDH1A1 (0.71) | POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4555634 | 0.73 | ALDH1A1 (0.71) | POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL733443 | 0.73 | GAA (0.70) | PKMPOLBALDH1A1 | |
| SCHEMBL13373156 | 0.71 | TDP1 (0.58) | POLBTDP1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14777565 | 0.71 | ALDH1A1 (0.57) | PKMTDP1L3MBTL1USP2ALDH1A1 | |
| SCHEMBL10042201 | 0.71 | ALDH1A1 (1.00) | POLBTDP1L3MBTL1USP2ALDH1A1 | |
| SCHEMBL22433209 | 0.71 | ALDH1A1 (0.69) | L3MBTL1ALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | PKM 4535/4885POLB 4461/4885TDP1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.